We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Kamada Ltd | NASDAQ:KMDA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.19 | 3.42% | 5.75 | 4.97 | 6.02 | 5.78 | 5.52 | 5.62 | 34,826 | 01:00:00 |
99.1 |
News Release: Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
|
Date: July 20, 2017
|
KAMADA LTD.
|
|
By:
/s/ Gil Efron
|
||
Gil Efron
Deputy Chief Executive Officer and Chief Financial Officer |
EXHIBIT NO.
|
DESCRIPTION
|
99.1
|
News Release: Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
|
1 Year Kamada Chart |
1 Month Kamada Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions